REPLIMUNE GROUP INC

Insider selling in a bull‑run: Sarchi Christopher’s 12k‑share sale at $9.24 shows disciplined liquidity management amid Replimune’s 229% rally and upcoming RP1 milestone.

Replimune’s latest option grant from Baker Bros. Advisors signals strong confidence in the company’s oncolytic immunotherapy pipeline and hints at future upside for investors.

Replimune insider activity shows a balanced tax‑efficient strategy with RSU sales and new ESO purchases, hinting at executive confidence in the oncolytic immunotherapy pipeline and potential upside for investors.

Insider buying surge signals confidence in Replimune’s oncolytic immunotherapy pipeline, boosting investor sentiment as clinical milestones loom.

Insider buying spurs confidence in Replimune Group (RPGC)—a biotech poised for growth as executives acquire stock and options, hinting at a potential breakout.

Insider sale of Replimune shares by CCO Sarchi Christopher hints at cautious confidence amid a looming FDA review of RP1—evaluate the impact on the company’s $694 m market cap.